Lildholdt T, Rundcrantz H, Lindqvist N
Department of Otolaryngology, Vejle Hospital, Denmark.
Clin Otolaryngol Allied Sci. 1995 Feb;20(1):26-30. doi: 10.1111/j.1365-2273.1995.tb00007.x.
Budesonide has been used for a number of years as a topical nasal corticosteroid in the treatment of nasal allergy and nasal polyps. Recently, a new device for powder insufflation where no constituents or preservatives are included has been developed (Rhinocort Turbuhaler, Astra Draco AB, Sweden). The present investigation was designed in order to study the efficacy of topical budesonide powder as the only treatment of nasal polyps. A total of 126 patients entered the study. The medical history and clinical recordings included symptoms and signs, a semiquantitative test of smell and measurement of nasal expiratory peak flow index. Medication was either 200 or 400 micrograms of budesonide powder b.i.d. or placebo. After 1 month an overall assessment of treatment efficacy was made to determine whether the treatment had been a success or a failure. The results showed a statistically significant improvement of symptoms and signs in the actively treated groups. The increase in expiratory peak flow index was about 60% in the actively treated groups as opposed to 16% in the placebo group. The overall assessment of treatment efficacy showed success in about 82% of actively treated patients as opposed to about 43% in the placebo group. It is concluded that budesonide powder is useful in the treatment of nasal polyps.
布地奈德作为一种局部鼻用皮质类固醇药物，已被用于治疗鼻过敏和鼻息肉多年。最近，一种新型的不含任何成分或防腐剂的粉末吸入装置已被研发出来（瑞典阿斯特拉·德拉科公司生产的雷诺考特都保）。本研究旨在探讨布地奈德粉末作为鼻息肉唯一治疗方法的疗效。共有126名患者参与了该研究。病史和临床记录包括症状和体征、嗅觉的半定量测试以及鼻呼气峰值流量指数的测量。用药为每日两次，每次200或400微克布地奈德粉末或安慰剂。1个月后，对治疗效果进行全面评估，以确定治疗是成功还是失败。结果显示，积极治疗组的症状和体征有统计学意义上的显著改善。积极治疗组的呼气峰值流量指数增加约60%，而安慰剂组为16%。治疗效果的全面评估显示，约82%的积极治疗患者治疗成功，而安慰剂组约为43%。结论是布地奈德粉末对鼻息肉治疗有效。
